Oxford BioMedica looks to move on from a challenging 2008

pharmafile | March 13, 2009 | News story | Sales and Marketing Oxford BioMedica, biotech 

Related Content

Oxford Biomedica acquires ABL Europe for €15m

Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut …

shutterstock_gonnorrhea

Industry comes together to form the AMR Action Fund, pledging $1bn to fight antimicrobial resistance

Over 20 biopharma firms have come together to launch the AMR Action Fund, an initiative …

shutterstock_2

Oxford Biomedica joins forces with UK’s Vaccines Manufacturing and Innovation Centre to scale up production of Oxford Uni’s COVID-19 vaccine

Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) …

Latest content